for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vir Biotechnology Inc

VIR.O

Latest Trade

17.38USD

Change

0.32(+1.88%)

Volume

278,144

Today's Range

17.11

 - 

18.15

52 Week Range

11.65

 - 

29.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
17.06
Open
17.11
Volume
278,144
3M AVG Volume
6.52
Today's High
18.15
Today's Low
17.11
52 Week High
29.00
52 Week Low
11.65
Shares Out (MIL)
109.68
Market Cap (MIL)
1,906.22
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Vir Biotechnology Reports Q3 Loss Per Share Of $4.60

Vir Biotechnology Shares Open 19.3% Below IPO Price In Debut

Vir Biotechnology Says IPO Priced At $20.00/Share

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vir Biotechnology Inc

Vir Biotechnology, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments to treat and prevent serious infectious diseases. Its technology platforms are focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid (siRNA). Its pipeline consists of product candidates targeting hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). Its product candidates include VIR-2218, VIR-3434, VIR-2482, VIR-1111 and VIR-2020. The Company is developing VIR-2218 and VIR-3434 for the functional cure of HBV. VIR-2218 is a subcutaneously administered HBV-targeting siRNA. VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody (mAb). VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb. VIR-1111 is a subcutaneously administered HIV T cell vaccine. VIR-2020 is a subcutaneously administered TB T cell vaccine.

Contact Info

499 Illinois St Ste 500

+1.415.9064324

https://www.vir.bio/

Executive Leadership

Vicki L. Sato

Independent Chairman of the Board

George A. Scangos

President, Chief Executive Officer, Director

Jay Parrish

Chief Business Officer

Howard Horn

Chief Financial Officer, Secretary

Virgin Virgin

Executive Vice President of Research and Chief Scientific Officer

Key Stats

2.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019(E)

0.0K
EPS (USD)

2019(E)

-2.358
Price To Earnings (TTM)
--
Price To Sales (TTM)
186.21
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.31
LT Debt To Equity (MRQ)
0.25
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Vir Biotechnology Identifies Two Antibodies That Bind To The Spike Protein Of 2019-Ncov, Newly Named As Sars-Cov-2

* VIR BIOTECHNOLOGY IDENTIFIES TWO ANTIBODIES THAT BIND TO THE SPIKE PROTEIN OF 2019-NCOV, NEWLY NAMED AS SARS-COV-2

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up